References
-
Ahmadian, M., Suh, J.M., Hah, N., Liddle, C., Atkins, A.R., Downes, M., and Evans, R.M. (2013).
$PPAR{\gamma}$ signaling and metabolism: the good, the bad and the future. Nat. Med. 99, 557. https://doi.org/10.1038/nm.3159 - Alfadda, A.A., Sallam, R.M., Gul, R., Hwang, I., and Ka, S. (2017). Endophilin A2: a potential link to adiposity and beyond. Mol. Cells 40, 855-863.
- Berria, R., Glass, L., Mahankali, A., Miyazaki, Y., Monroy, A., De Filippis, E., Cusi, K., Cersosimo, E., Defronzo, R.A., and Gastaldelli, A. (2007). Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin. Pharmacol. Therap. 82, 275-281. https://doi.org/10.1038/sj.clpt.6100146
-
Bouhlel, M.A., Derudas, B., Rigamonti, E., Dievart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007).
$PPAR{\gamma}$ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabol. 6, 137-143. https://doi.org/10.1016/j.cmet.2007.06.010 - Carriere, A., Jeanson, Y., Berger-Muller, S., Andre, M., Chenouard, V., Arnaud, E., Barreau, C., Walther, R., Galinier, A., Wdziekonski, B., et al. (2014). Browning of white adipose cells by intermediate metabolites: an adaptive mechanism to alleviate redox pressure. Diabetes 63, 3253-3265. https://doi.org/10.2337/db13-1885
- Choe, S.S., Huh, J.Y., Hwang, I.J., Kim, J.I., and Kim, J.B. (2016). Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front. Endocrinol. 7, 30.
- Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Bostrom, P., Laznik, D., Ruas, J.L., Chalmers, M.J., Kamenecka, T.M., Bluher, M., et al. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456. https://doi.org/10.1038/nature09291
- Fonseca, V.A. (2009). Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 Suppl 2, S151-156. https://doi.org/10.2337/dc09-S301
- Gross, B., Pawlak, M., Lefebvre, P., and Staels, B. (2017). PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat. Rev. Endocrinol. 13, 36-49. https://doi.org/10.1038/nrendo.2016.135
- He, H., Tao, H., Xiong, H., Duan, S.Z., McGowan, F.X., Jr., Mortensen, R.M., and Balschi, J.A. (2014). Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-independent mitochondrial oxidative stress in mouse hearts. Toxicol. Sci. 138, 468-481. https://doi.org/10.1093/toxsci/kfu015
- Huh, J.Y., Park, Y.J., Ham, M., and Kim, J.B. (2014). Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol. Cells 37, 365-371. https://doi.org/10.14348/molcells.2014.0074
- Ikeda, K., Maretich, P., and Kajimura, S. (2018). The common and distinct features of brown and beige adipocytes. Trends Endocrinol. Metabol. 29, 191-200. https://doi.org/10.1016/j.tem.2018.01.001
-
Jang, J.Y., Bae, H., Lee, Y.J., Choi, Y.I., Kim, H.J., Park, S.B., Suh, S.W., Kim, S.W., and Han, B.W. (2018). Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on
$PPAR{\gamma}$ . Sci. Rep. 8, 31. https://doi.org/10.1038/s41598-017-18274-1 - Jenssen, T., and Hartmann, A. (2015). Emerging treatments for post-transplantation diabetes mellitus. Nat. Rev. Nephrol. 11, 465-477. https://doi.org/10.1038/nrneph.2015.59
- Jin, S.M., Park, C.Y., Cho, Y.M., Ku, B.J., Ahn, C.W., Cha, B.S., Min, K.W., Sung, Y.A., Baik, S.H., Lee, K.W., et al. (2015). Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes. Metabol. 17, 599-602. https://doi.org/10.1111/dom.12435
- Kahn, S.E., Haffner, S.M., Heise, M.A., Herman, W.H., Holman, R.R., Jones, N.P., Kravitz, B.G., Lachin, J.M., O'Neill, M.C., Zinman, B., et al. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl J. Med. 355, 2427-2443. https://doi.org/10.1056/NEJMoa066224
- Kim, J.I., Huh, J.Y., Sohn, J.H., Choe, S.S., Lee, Y.S., Lim, C.Y., Jo, A., Park, S.B., Han, W., and Kim, J.B. (2015a). Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation. Mol. Cell Biol. 35, 1686-1699. https://doi.org/10.1128/MCB.01321-14
- Kim, S.H., Kim, S.G., Kim, D.M., Woo, J.T., Jang, H.C., Chung, C.H., Ko, K.S., Park, J.H., Park, Y.S., Kim, S.J., et al. (2015b). Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. Diabetes Res. Clin. Pract. 110, e27-30. https://doi.org/10.1016/j.diabres.2015.09.009
- Kim, G., Lee, Y.H., Yun, M.R., Lee, J.Y., Shin, E.G., Lee, B.W., Kang, E.S., and Cha, B.S. (2017a). Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice. Int. J. Obes. 42, 545-551.
- Kim, K.M., Jin, H.J., Lee, S.Y., Maeng, H.J., Lee, G.Y., Oh, T.J., Choi, S.H., Jang, H.C., and Lim, S. (2017b). Effects of lobeglitazone, a new thiazolidinedione, on osteoblastogenesis and bone mineral density in mice. Endocrinol. Metabol. 32, 389-395. https://doi.org/10.3803/EnM.2017.32.3.389
- Kohlroser, J., Mathai, J., Reichheld, J., Banner, B.F., and Bonkovsky, H.L. (2000). Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gastroenterol. 95, 272-276. https://doi.org/10.1111/j.1572-0241.2000.01707.x
- Lee, H.W., Kim, B.Y., Ahn, J.B., Kang, S.K., Lee, J.H., Shin, J.S., Ahn, S.K., Lee, S.J., and Yoon, S.S. (2005). Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur. J. Med. Chem. 40, 862-874. https://doi.org/10.1016/j.ejmech.2005.03.019
- Lee, J.H., Woo, Y.A., Hwang, I.C., Kim, C.Y., Kim, D.D., Shim, C.K., and Chung, S.J. (2009). Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. J. Pharm. Biomed. Anal. 50, 872-877. https://doi.org/10.1016/j.jpba.2009.06.003
- Lee, H.S., Chang, M., Lee, J.E., Kim, W., Hwang, I.C., Kim, D.H., Park, H.K., Choi, H.J., Jo, W., Cha, S.W., et al. (2014a). Carcinogenicity study of CKD-501, a novel dual peroxisome proliferator-activated receptors alpha and gamma agonist, following oral administration to Sprague Dawley rats for 94-101 weeks. Regul. Toxicol. Pharmacol. 69, 207-216. https://doi.org/10.1016/j.yrtph.2014.04.003
- Lee, J.H., Lee, G.Y., Jang, H., Choe, S.S., Koo, S.H., and Kim, J.B. (2014b). RNF20 regulates hepatic lipid metabolism through PKA-dependent SREBP1c degradation. Hepatology 60, 844-857. https://doi.org/10.1002/hep.27011
- Lee, M.A., Tan, L., Yang, H., Im, Y.G., and Im, Y.J. (2017). Structures of PPARgamma complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Sci. Rep. 7, 16837. https://doi.org/10.1038/s41598-017-17082-x
-
Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M., and Kliewer, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor
${\gamma}$ ($PPAR{\gamma}$ ). J. Biol. Chem. 270, 12953-12956. https://doi.org/10.1074/jbc.270.22.12953 - Li, Y., Wang, Z., Furukawa, N., Escaron, P., Weiszmann, J., Lee, G., Lindstrom, M., Liu, J., Liu, X., Xu, H., et al. (2008). T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. J. Biol. Chem. 283, 9168-9176. https://doi.org/10.1074/jbc.M800104200
- Lim, S., Lee, K.S., Lee, J.E., Park, H.S., Kim, K.M., Moon, J.H., Choi, S.H., Park, K.S., Kim, Y.B., and Jang, H.C. (2015). Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 243, 107-119. https://doi.org/10.1016/j.atherosclerosis.2015.08.037
- Moon, K.S., Lee, J.E., Lee, H.S., Hwang, I.C., Kim, D.H., Park, H.K., Choi, H.J., Jo, W., Son, W.C., and Yun, H.I. (2014). CKD-501, a novel selective PPARgamma agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks. J. Appl. Toxicol. 34, 1271-1284. https://doi.org/10.1002/jat.2918
-
Nedergaard, J., Petrovic, N., Lindgren, E.M., Jacobsson, A., and Cannon, B. (2005).
$PPAR{\gamma}$ in the control of brown adipocyte differentiation. Biochim. Biophys. Acta. 1740, 293-304. https://doi.org/10.1016/j.bbadis.2005.02.003 - Nissen, S.E., and Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng. J. Med. 356, 2457-2471. https://doi.org/10.1056/NEJMoa072761
- Ohno, H., Shinoda, K., Spiegelman, B.M., and Kajimura, S. (2012). PPAR agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metabol. 15, 395-404. https://doi.org/10.1016/j.cmet.2012.01.019
- Olefsky, J.M., and Glass, C.K. (2010). Macrophages, inflammation, and insulin resistance. Ann. Rev. Physiol. 72, 219-246. https://doi.org/10.1146/annurev-physiol-021909-135846
- Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, S.R., et al. (2012). Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell 150, 620-632. https://doi.org/10.1016/j.cell.2012.06.027
- Rizos, C.V., Elisaf, M.S., Mikhailidis, D.P., and Liberopoulos, E.N. (2009). How safe is the use of thiazolidinediones in clinical practice? Exp. Opin. Drug Safety 8, 15-32. https://doi.org/10.1517/14740330802597821
- Rothwell, N.J., Stock, M.J., and Tedstone, A.E. (1987). Effects of ciglitazone on energy balance, thermogenesis and brown fat activity in the rat. Mol. Cell. Endocrinol. 51, 253-257. https://doi.org/10.1016/0303-7207(87)90035-9
- Semple, R.K., Chatterjee, V.K., and O'Rahilly, S. (2006). PPAR gamma and human metabolic disease. J. Clin. Invest. 116, 581-589. https://doi.org/10.1172/JCI28003
- Soccio, R.E., Chen, E.R., and Lazar, M.A. (2014). Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metabol. 20, 573-591. https://doi.org/10.1016/j.cmet.2014.08.005
- Sohn, J.H., Lee, Y.K., Han, J.S., Jeon, Y.G., Kim, J.I., Choe, S.S., Kim, S.J., Yoo, H.J., and Kim, J.B. (2018). Perilipin 1 (Plin1) deficiency promotes inflammatory responses in lean adipose tissue through lipid dysregulation. J. Biol. Chem. pii: jbc.RA118.003541.
- Sola, D., Rossi, L., Schianca, G.P.C., Maffioli, P., Bigliocca, M., Mella, R., Corliano, F., Fra, G.P., Bartoli, E., and Derosa, G. (2015). Sulfonylureas and their use in clinical practice. Arch. Med. Sci. 11, 840-848.
- Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. (2006). Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96.
- Tontonoz, P., and Spiegelman, B.M. (2008). Fat and beyond: the diverse biology of PPARgamma. Ann. Rev. Biochem. 77, 289-312. https://doi.org/10.1146/annurev.biochem.77.061307.091829
- Yau, H., Rivera, K., Lomonaco, R., and Cusi, K. (2013). The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr. Diabetes Rep. 13, 329-341. https://doi.org/10.1007/s11892-013-0378-8
- Yki-Jarvinen, H. (2004). Thiazolidinediones. N Engl. J. Med. 351, 1106-1118. https://doi.org/10.1056/NEJMra041001
Cited by
- During Adipocyte Remodeling, Lipid Droplet Configurations Regulate Insulin Sensitivity through F-Actin and G-Actin Reorganization vol.39, pp.20, 2018, https://doi.org/10.1128/mcb.00210-19
- RNF20 Functions as a Transcriptional Coactivator for PPARγ by Promoting NCoR1 Degradation in Adipocytes vol.69, pp.1, 2018, https://doi.org/10.2337/db19-0508
- An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men vol.42, pp.6, 2018, https://doi.org/10.1016/j.clinthera.2020.04.005
- Browning of White Adipose Tissue as a Therapeutic Tool in the Fight against Atherosclerosis vol.11, pp.5, 2018, https://doi.org/10.3390/metabo11050319
- Fruit of Gardenia jasminoides Induces Mitochondrial Activation and Non-Shivering Thermogenesis through Regulation of PPARγ vol.10, pp.9, 2018, https://doi.org/10.3390/antiox10091418
- Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues vol.10, pp.11, 2018, https://doi.org/10.3390/cells10113030
- Spatial Regulation of Reactive Oxygen Species via G6PD in Brown Adipocytes Supports Thermogenic Function vol.70, pp.12, 2018, https://doi.org/10.2337/db21-0272